

DAFTAR PUSTAKA

1. More C, Dabhade P., Jain N., Aher B. Solubility and Dissolution Enhancement of Gliclazide. *Int J Pharm Chem Anal.* 2015;2:51–8.
2. Swamy Lakka N, Goswami N. Solubility and Dissolution Profile Studies of Gliclazide in Pharmaceutical Formulations By RP-HPLC. *Int Res J Pharm.* 2012;3(6):126–9.
3. Bollish SJ. *Applied Biopharmaceutics and Pharmacokinetics.* 7th ed. Vol. 38, American Journal of Health-System Pharmacy. United State: McGraw-Hill Education; 2019. 1400–1404.
4. Dukhan AAM, Amalina N, Kyaw Oo M, Sengupta P, Doolaanea AAM, Aljapairai KAS, et al. Formulation of Dispersed Gliclazide Powder in Polyethylene Glycol–Polyvinyl Caprolactam– Polyvinyl Acetate Grafted Copolymer Carrier for Capsulation and Improved Dissolution. *Indian J Pharm Educ Res.* 2018;52(4s):S210–9.
5. Grothe E, Meekes H, Vlieg E, Horst J, Gelder RD. Solvates, salts, and cocrystals: A proposal for a feasible classification system. *Cryst Growth.* 2016;15(6):3237–43.
6. Shinde U, Desai H, Martis EAF, Amin P. Co-crystals of Gliclazide : Formulation and Characterisation. *Am J PharmTech Res.* 2017;7(2):217–35.
7. Reddy MN, Anusha P, Professor A. Development and Characterisation of Gliclazide Cocrystals. *Int J Pharm Biol Sci.* 2018;8(1):22–32.
8. Prawiro WS, Murtini G, Suprapti T, Cartika H. Enhancing Dissolution Rates of Gliclazide Via Cocrystallization with Nicotinamide. *Asian J Appl Sci.* 2016;4(4):899–905.
9. Jones W, Motherwell WDS, Trask A V. Pharmaceutical Cocrystals: An Emerging Approach to Physical Property Enhancement. *MRS Bull.* 2006;31(11):875–9.
10. Food and Drug Administration. Guidance for Industry Regulatory Classification of Pharmaceutical Co-Crystals Guidance for Industry Regulatory Classification of Pharmaceutical Co-Crystals. Fda. New Hampshire Ave: U.S. Department of Health and Human Services; 2013. 1–5.
11. Cvetkovski A, Ferretti V, Bertolasi V. New Pharmaceutical Salts Containing Pyridoxine. *Acta Crystallogr Sect C Struct Chem.* 2017;73(12):1064–70.
12. Vishweshwar P, McMahon JA, Zaworotko MJ. Crystal Engineering of Pharmaceutical Co-crystals. *Frontiers in Crystal Engineering.* University of South Florida; 2006.
13. Yadav B, Balasubramanian S, Chavan RB, Thipparaboina R, Naidu VGM, Shastri NR. Hepatoprotective Cocrystals and Salts of Riluzole: Prediction,

- Synthesis, Solid State Characterization, and Evaluation. *Cryst Growth Des.* 2018;18(2):1047–61.
14. Departemen Kesehatan Republik Indonesia. *Farmakope Indonesia Edisi V.* Jakarta: Departemen Kesehatan RI; 2014.
 15. Maggi L, Canobbio A, Bruni G, Musitelli G, Conte U. Improvement of The Dissolution Behavior of Gliclazide, A Slightly Soluble Drug, Using Solid Dispersions. *J Drug Deliv Sci Technol.* 2015;26:17–23.
 16. Sambath L, Kottai Muthu A, Ashis Kumar M, Phaneendra K, Shalini. Physicochemical Characterization and In-vitro Dissolution Behavior of Gliclazide. *Int J Pharm Pharm Sci.* 2013;5(2):204–10.
 17. Shavi G, Kumar A, Usha Y, Armugam K, Ranjan O, Ginjupalli K, et al. Enhanced Dissolution and Bioavailability of Gliclazide Using Solid Dispersion Techniques. *Int J Drug Deliv.* 2010;2(1):49–57.
 18. National Center for Biotechnology Information. Syringic Acid [Internet]. PubChem Database. [cited 2019 Apr 28]. Available from: <https://pubchem.ncbi.nlm.nih.gov/compound/10742>
 19. Cayman Chemical Company. *Syringic Acid.* Amerika Serikat: Cayman Chemical Company; 2016.
 20. Byrn SR, Pfeiffer R, Stowell J. *Solid-State Chemistry of Drug.* West Lafayette: SSCI; 1999.
 21. Hancock BC, Parks M. What is The True Solubility Advantage for Amorphous Pharmaceutical? *Pharm Res.* 2000;17:397–404.
 22. Yoshioka S, Aso Y. Correlation Between Molecular Mobility and Chemical Stability During Storage of Amorphous Pharmaceutical. *J Pharmaceutical Sci Res.* 2007;96:960–81.
 23. Andronis V, Zografis G. Crystal Nucleation and Growth of Indomethacin Polimorphs from The Amorphous State. *J Non Cryst Solids.* 2000;271:236–48.
 24. Cruz-Cabeza AJ. Acid Base Crystalline Complex and The pKa Rule. *Cryst Eng Commun.* 2012;14:6362–5.
 25. Zaini E, Sumirtapura Y, Soewandhi S, Halim A. Identifikasi Interaksi Fisika antara Trimetoprim dan Sulfametoksazol dengan Metode Kontak Kofler dan Reaksi Kristalisasi. *Maj Farm Indones.* 2010;21(1):32–6.
 26. Zaini E, Halim A, Soewandhi SN, Setyawan D. Peningkatan Laju Pelarutan Trimetoprim Melalui Metode Ko-Kristalisasi dengan Nikotinamida. *J Farm Indones.* 2011;5(4):205–12.
 27. Mirza S, Heinämäki J, Miroshnyk I, Yliruusi J. An Emerging Approach to Improving Properties of Pharmaceutical Solids. *Eur J Pharm Sci.* 2008;34(1):90–6.
 28. Chadha R, Saini A, Arora P, Chanda S, Dharamvirsingh Jain. Cocrystals of Efavirenz with Selected Coformers. *Int J Pharm Pharm Sci.* 2012;4(2):244–50.



29. Yadav A, Shete A, Dabke A, Kulkarni P, Sakhare S. A Novel Approach to Modify Physicochemical Properties of Active Pharmaceutical Ingredients. *Indian J Pharm Sci.* 2009;71(4):359–70.
30. Perlovich GL, Manin AN. Design of Pharmaceutical Cocrystals for Drug Solubility Improvement. *Russ J Gen Chem.* 2014;84(2):407–14.
31. Qiao N, Li M, Schlindwein W, Malek N, Davies A, Trappitt G. Pharmaceutical cocrystals: An overview. *Int J Pharm* [Internet]. 2011;419(1–2):1–11. Available from: <http://dx.doi.org/10.1016/j.ijpharm.2011.07.037>
32. Aakeroy C, Grommet AB, Desper J. Co-crystal or salt: does it really matter? *Mol Pharm.* 2007;4(3):317–22.
33. Desiraju GR. Supramolecular Synthons in Crystal Engineering. *Angew Chemie Int Ed English.* 1995;34(21):2311–2327.
34. Bhogala BKR. Tape and Layer Structures in Cocrystals of Some Di- and Tricarboxylic acids with 4,4'-bipyridines and Isonicotinamide. *Cryst Eng Commun.* 2005;7:551–62.
35. Upadhyay N, Shukla TP, Mathur A, Manmohana, Jha SK. An Emerging Approach to Improve Physical Property. *Int J Pharm Sci Rev Res.* 2011;8(1):144–8.
36. Jayasankar A, Somwangthanaroj A, Shao ZJ. Cocrystal Formation during Cogrinding and Storage is Mediated by Amorphous Phase. *Pharm Res.* 2006;23(10):2381–92.
37. Basavoju S, Bostro D. Indomethacin–Saccharin Cocrystal: Design, Synthesis and Preliminary Pharmaceutical Characterization. *Pharm Res.* 2008;25(3):530–41.
38. Tiwari S, Verma P. Microencapsulation Technique by Solvent Evaporation Method. *Int J Pharm Life Sci.* 2011;2(8):998–1005.
39. Trask A V., Haynes DA, Motherwell WDS, Jones W. Screening for Crystalline Salts Via Mechanochemistry. *Chem Commun.* 2006;(1):51–3.
40. Kotak U, Prajapati V, Solanki H, Jani G, Jha P. Co-crystallization Technique - Its rationale and recent progress. *World J Pharm Pharm Sci.* 2015;4(04):1484–508.
41. Vasconcelos T filo, Sarmiento B, Costa P. Solid Dispersions As Strategy to Improve Oral Bioavailability of Poor Water Soluble Drugs. *Drug Discov Today.* 2007;12(23):1068–75.
42. Leuner C, Dressman J. Improving Drug Solubility for Oral Delivery Using Solid Dispersion. *Eur J Pharm Biopharm.* 2000;6411(1):47–60.
43. Vitthalrao MA, Kumar FN, Radheshyam BK. An Alternative Approach for Solid Modification. *J Drug Deliv Ther.* 2013;3(4):166–72.
44. Arthur Cammarata, Martin A, Swarbrick J. *Farmasi Fisik.* Jakarta: UI Press; 1990. 559–61.

45. Ansel HC. Pengantar Bentuk Sediaan Farmasi. 4th ed. Vol. Edisi IV, Jakarta: UI-Press. Jakarta: UI Press; 1989. 214-7.
46. Chaudhary A, Nagaich U, Gulati N, Sharma VK, Khosa RL. Enhancement of Solubilization and Bioavailability of Poorly Soluble Drugs by Physical and Chemical Modifications. *J Adv Pharm Educ Res.* 2012;2(1):32–67.
47. Basanta Kumar Reddy B, Karunakar A. Biopharmaceutics Classification System. *Dissolution Technol.* 2011;18(1):31–7.
48. Siregar CJP, Wikarsa S. Dasar-Dasar Praktis Teknologi Farmasi Sediaan Tablet. Jakarta: EGC; 2010.
49. Popy FA, Dewan I, Parvin MN, Ashraful Islam SM. Evaluation of In Vitro Equivalence for Tablets Containing The Poorly Water-Soluble Compound Atorvastatin. *Dissolution Technol.* 2012;19(4):30–3.
50. Allen L V, Popovich NG, Ansel HC, Ansel's Pharmaceutical Drug Delivery System. 9th ed. Troy DB, editor. Philadelphia: Lippincott Williams & Wilkins; 2011.
51. Niazi SK. Handbook of Pharmaceutical Manufacturing. New York: Informa Healthcare USA, Inc; 2009.
52. Gantiaji CR, S TNS, Istikharah R. Uji Sifat Fisik, Kadar dan Disolusi Terbanding Generik Bermerek dan Inovator Tablet Karbamazepin Generik Berlogo, Generik Bermerek dan Inovator. Yogyakarta: Universitas Islam Indonesia; 2014.
53. Shargel L. Applied Biopharmaceutics and Pharmacokinetics. 7th ed. United State: The McGraw-Hill Companies; 2012.
54. Swarbick J. Encyclopedia of Pharmaceutical Technology. Vol. 40, Choice Reviews Online. New York: Informa Healthcare USA; 2013.
55. U.S Pharmacopeial Convention. The United States Pharmacopeia National Formulary. In: R, Ockville M: USPC, editors. USP30/NF25. Maryland: U.S Pharmacopeial Convention; 2011.
56. Rohman A. Kimia Farmasi Analisis. Yogyakarta: Pustaka Belajar; 2007.
57. Khopkar S. Konsep Dasar Kimia Analitik. Jakarta: Universitas Indonesia; 1990.
58. Satiadarma K, Mulja M, Tjahjono C., Kartasasmita R. Asas Pengembangan Prosedur Analisis. 1st ed. Surabaya: Airlangga University Press; 2004.
59. Munson J. Analisis Farmasi: Metode Modern. Surabaya: Airlangga University Press; 1984.
60. Dewi R, Krisman, Khaironiati, Fauziana. Karakterisasi Mikrostruktur Material Feroelektrik Ba_{0.8}Sr_{0.2}TiO₃ (BST) dengan Variasi Suhu Annealing. *J Fis Indones.* 2014;18(53):70–2.
61. Lorenzelli V. Basic Solid State Chemistry. 2nd ed. Vol. 21, Materials Chemistry and Physics. Toronto: John Wiley & Sons; 2003.
62. Gozali D, Bahti HH, Soewandhi SN, Abdassah M. Pembentukan Kokristal Antara Kalsium Atorvastatin dengan Isonikotinamid dan Karakterisasinya.

- J Sains Mater Indones. 2014;15(2):103–10.
63. Monzurul A, Mahmud H, Kibria G, Rahman H, Ruknuzzaman R, Reza U. Dissolution Enhancement of Poorly Soluble Carbamazepine By Using Polymeric Solid Dispersions. *Int J Pharm Sci Res.* 2010;2(1):49–57.
 64. Erlianti R, Darusman F, Herawati D. Praperlakuan Bahan Baku Glimepirid Melalui Metode Kokristalisasi Untuk Meningkatkan Kelarutan dan Laju Disolusi 1,2,3. *Pros Penelit Spes Unisba 2015 ISSN 2460-6472.* 2015;3:671–80.
 65. Friscic T, Childs S, Rizvic, Jonesa W. The Role of Solvent in Mechanochemical and Sonochemical Cocystal Formation: A Solubility-Based Approach for Predicting Cocrystallisation Outcome. *Cryst Eng Commun.* 2008;11:418–26.
 66. Biswal S, Sahoo J, Murthy PN. Characterisation of gliclazide-PEG 8000 solid dispersions. *Trop J Pharm Res.* 2009;8(5):417–24.
 67. Srinivasulu C, Ramgopal M, Ramanjaneyulu G, Anuradha C, Suresh KC. Syringic Acid (SA) - A Review of Its Occurance, Biosynthesis, Pharmacological and Industrial Importance. *Biomed Pharmacother.* 2018;108:547–57.
 68. Thipparaboina R, Mittapalli S, Thatikonda S, Nangia A, Naidu VGM, Shastri NR. Syringic Acid: Structural Elucidation and Co-Crystallization. *Cryst Growth Des.* 2016;16(8):4679–87.
 69. Davis R, Lorimer K, Wilkowski M, Rivers J. Studies of Relationship in Cocystal Systems. *Am Crystallogr Assoc Trans.* 2004;39:41–61.
 70. Putra OD., Etsuo Y, Hidehiro U. Isostructural Multicomponen Crystal with Improved Solubility. *Cryst Growth Des.* 2016;10:1–23.
 71. Cherukuvada S, Row T. Comprehending the formation of eutectics and cocrystals in terms of design and their structural interrelationships. *Cryst Growth Des.* 2014;14:4187–4198.
 72. Gaur P, Mishra S, Purohit S, Dave K. Transdermal drug delivery system: A review. *Asian J Pharm Clin Res.* 2009;2(1):14–20.
 73. Wardiyah, Asyarie S, Wikarsa S. Pembuatan dan Karakterisasi Dispersi Padat Sistem Biner dan Terner dari Gliklazid. *Acta Pharm Indones.* 2012;XXXVII(3):95–101.
 74. Dachriyanus. Analisis Struktur Senyawa Organik Secara Spektroskopi. Padang: Universitas Andalas; 2004.
 75. Zaini E, Wahyuni YS, Halim A, Yuliandra Y. Preparation of Eutectic Mixture of Ketoprofen and Nicotinamide for Enhanced Dissolution Rate. *Int J Pharm Sci Rev Res.* 2015;35(1):161–4.
 76. Ketan P. Dadhania, Parthika A. Nadpara YKA. Development and Validation of Spectrophotometric Method for Simultaneous Estimation of. *Ijnternational jopsr.* 2011;2(6):1559–63.
 77. Brittain HG. Profiles of Drug Substances, Excipients, and Related Methodology. Amerika Serikat: Academic Press; 2012.

78. Mali AD, Mali S, Tamboli A, Bathe R. Simultaneous UV Spectrophotometric Methods for Estimation of Metformin HCl and Glimepiride in Bulk and Tablet Dosage Form. *Int J Adv Pharm.* 2015;4(6):117–24.
79. Chowdary KPR, Hussainy SA. Formulation and evaluation of floating tablets of gliclazide employing HPMC and carbopol. *Int J Chem Sci.* 2012;10(3):1213–20.

